Karl D. Lewis
- Oncology top 0.2%
- Molecular Biology top 1%
- Immunology top 2%
- Epidemiology top 2%
- Dermatology top 0.2%
- Co-authors
- René GonzálezOmid HamidWilliam A. RobinsonAxel HauschildAnne Lynn S. ChangMichael R. MigdenSandra P. D’AngeloCélèste Lebbé
- Topics
- Melanoma and MAPK Pathways (62 papers)CAR-T cell therapy research (45 papers)Cancer Immunotherapy and Biomarkers (40 papers)
- Cited by
- OncologyDermatologyImmunology
- Partner nations
- United StatesGermanyAustralia
In The Last Decade
Karl D. Lewis
173 papers receiving 7.6k citations
Hit Papers
Peers
Comparison fields: 5 of 115
- Oncology 4.9k
- Molecular Biology 4.0k
- Immunology 1.5k
- Epidemiology 1.5k
- Dermatology 1.0k
Countries citing papers authored by Karl D. Lewis
This map shows the geographic impact of Karl D. Lewis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karl D. Lewis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karl D. Lewis more than expected).
Fields of papers citing papers by Karl D. Lewis
This network shows the impact of papers produced by Karl D. Lewis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karl D. Lewis. The network helps show where Karl D. Lewis may publish in the future.
Co-authorship network of co-authors of Karl D. Lewis
This figure shows the co-authorship network connecting the top 25 collaborators of Karl D. Lewis. A scholar is included among the top collaborators of Karl D. Lewis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karl D. Lewis. Karl D. Lewis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 14 | |
| 3 | 1 | |
| 4 | 4 | |
| 5 | 0 | |
| 6 | 2 | |
| 7 | 8 | |
| 8 | 30 | |
| 9 | 8 | |
| 10 | 137 | |
| 11 | 17 | |
| 12 | 3 | |
| 13 | 154 | |
| 14 | 46 | |
| 15 | 356 | |
| 16 | 14 | |
| 17 | 7 | |
| 18 | 176 | |
| 19 | 10 | |
| 20 | A phase II study of YM155 administered as 168 hour continuous infusion in stage IV and unresectable stage III melanoma. | 4 |
About Karl D. Lewis
Karl D. Lewis is a scholar working on Oncology, Dermatology and Molecular Biology, having authored 177 papers that have together received 7.8k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (62 papers), CAR-T cell therapy research (45 papers) and Cancer Immunotherapy and Biomarkers (40 papers). The work is most often cited by research in Oncology (4.9k citations), Dermatology (1.0k citations) and Immunology (1.5k citations). Karl D. Lewis has collaborated with scholars based in United States, Germany and Australia. Frequent co-authors include René González, Omid Hamid, William A. Robinson, Axel Hauschild, Anne Lynn S. Chang, Michael R. Migden, Sandra P. D’Angelo, Célèste Lebbé, Isaac Brownell and Kent C. Shih. Their work appears in journals such as New England Journal of Medicine, The Lancet and Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.